Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Deviation from expected cognitive ability is a core cognitive feature of schizophrenia related to neurophysiologic, clinical and psychosocial functioning.

Hochberger WC, Thomas ML, Joshi YB, Swerdlow NR, Braff DL, Gur RE, Gur RC, Light GA; Consortium of Genomics in Schizophrenia (COGS) investigators.

Schizophr Res. 2019 Nov 16. pii: S0920-9964(19)30442-6. doi: 10.1016/j.schres.2019.10.011. [Epub ahead of print]

PMID:
31744751
2.

Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study.

Greenwood TA, Lazzeroni LC, Maihofer AX, Swerdlow NR, Calkins ME, Freedman R, Green MF, Light GA, Nievergelt CM, Nuechterlein KH, Radant AD, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Gur RC, Gur RE, Braff DL.

JAMA Psychiatry. 2019 Oct 9. doi: 10.1001/jamapsychiatry.2019.2850. [Epub ahead of print]

PMID:
31596458
3.

Commentary: Lessons Learned From Animal Models for Schizophrenia.

Swerdlow NR.

Am J Geriatr Psychiatry. 2020 Jan;28(1):20-22. doi: 10.1016/j.jagp.2019.08.019. Epub 2019 Aug 24. No abstract available.

PMID:
31542196
4.

Selection criteria for neurophysiologic biomarkers to accelerate the pace of CNS therapeutic development.

Light GA, Swerdlow NR.

Neuropsychopharmacology. 2020 Jan;45(1):237-238. doi: 10.1038/s41386-019-0519-0. No abstract available.

PMID:
31506611
5.

Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.

Swerdlow NR, Bhakta SG, Talledo J, Benster L, Kotz J, Lavadia M, Light GA.

Neuropsychopharmacology. 2019 Dec;44(13):2277-2284. doi: 10.1038/s41386-019-0495-4. Epub 2019 Aug 24.

PMID:
31445502
6.

Nonlinear dynamics underlying sensory processing dysfunction in schizophrenia.

Lainscsek C, Sampson AL, Kim R, Thomas ML, Man K, Lainscsek X; COGS Investigators, Swerdlow NR, Braff DL, Sejnowski TJ, Light GA.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3847-3852. doi: 10.1073/pnas.1810572116. Epub 2019 Feb 11.

7.

Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients.

Joshi YB, Thomas ML, Hochberger WC, Bismark AW, Treichler EBH, Molina J, Nungaray J, Cardoso L, Sprock J, Swerdlow NR, Light GA.

Schizophr Res. 2019 Jun;208:384-389. doi: 10.1016/j.schres.2019.01.016. Epub 2019 Feb 6.

PMID:
30738698
8.

Decomposing the constituent oscillatory dynamics underlying mismatch negativity generation in schizophrenia: Distinct relationships to clinical and cognitive functioning.

Hochberger WC, Joshi YB, Zhang W, Thomas ML; Consortium of Genomics in Schizophrenia (COGS) investigators, Braff DL, Swerdlow NR, Light GA.

Int J Psychophysiol. 2019 Nov;145:23-29. doi: 10.1016/j.ijpsycho.2018.12.014. Epub 2018 Dec 23.

PMID:
30586570
9.

Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.

Kantrowitz JT, Swerdlow NR, Dunn W, Vinogradov S.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Jul;3(7):581-590. doi: 10.1016/j.bpsc.2018.02.002. Epub 2018 Feb 22. Review.

10.

Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.

Swerdlow NR, Bhakta SG, Light GA.

Schizophr Res. 2018 Sep;199:285-291. doi: 10.1016/j.schres.2018.03.037. Epub 2018 Apr 5.

11.

Sensorimotor gating deficits in schizophrenia: Advancing our understanding of the phenotype, its neural circuitry and genetic substrates.

Swerdlow NR, Light GA.

Schizophr Res. 2018 Aug;198:1-5. doi: 10.1016/j.schres.2018.02.042. Epub 2018 Mar 7. No abstract available.

12.

Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.

Swerdlow NR, Bhakta SG, Talledo JA, Franz DM, Hughes EL, Rana BK, Light GA.

Neuropsychopharmacology. 2018 Mar;43(4):708-717. doi: 10.1038/npp.2017.285. Epub 2017 Nov 20.

13.

Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors.

Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, Rana BK, Young JW, Swerdlow NR.

Int J Neuropsychopharmacol. 2017 Dec 1;20(12):979-987. doi: 10.1093/ijnp/pyx074.

14.

A Upf3b-mutant mouse model with behavioral and neurogenesis defects.

Huang L, Shum EY, Jones SH, Lou CH, Dumdie J, Kim H, Roberts AJ, Jolly LA, Espinoza JL, Skarbrevik DM, Phan MH, Cook-Andersen H, Swerdlow NR, Gecz J, Wilkinson MF.

Mol Psychiatry. 2018 Aug;23(8):1773-1786. doi: 10.1038/mp.2017.173. Epub 2017 Sep 26.

15.

Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension.

Swerdlow NR, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2018 Aug;198:6-15. doi: 10.1016/j.schres.2017.05.013. Epub 2017 May 24.

16.

Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.

Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR.

Neuropsychopharmacology. 2017 Dec;42(13):2633-2639. doi: 10.1038/npp.2017.81. Epub 2017 Apr 20.

17.

Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia.

Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlow NR, Light GA.

Neuropsychopharmacology. 2017 Oct;42(11):2206-2213. doi: 10.1038/npp.2017.25. Epub 2017 Jan 31.

18.

Sensorimotor gating in healthy adults tested over a 15 year period.

Swerdlow NR, Bhakta SG, Rana BK, Kei J, Chou HH, Talledo JA.

Biol Psychol. 2017 Feb;123:177-186. doi: 10.1016/j.biopsycho.2016.12.011. Epub 2016 Dec 24.

19.

Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia.

Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Light GA.

JAMA Psychiatry. 2017 Jan 1;74(1):37-46. doi: 10.1001/jamapsychiatry.2016.2980.

20.

Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.

Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, Rana B, Vinogradov S, Light GA.

Schizophr Bull. 2017 Jul 1;43(4):872-880. doi: 10.1093/schbul/sbw148.

21.

Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next.

Swerdlow NR, Braff DL, Geyer MA.

J Psychopharmacol. 2016 Nov;30(11):1072-1081. Epub 2016 Aug 18. Review.

22.

Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges.

Cope ZA, Halberstadt AL, van Enkhuizen J, Flynn AD, Breier M, Swerdlow NR, Geyer MA, Young JW.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3513-25. doi: 10.1007/s00213-016-4389-4. Epub 2016 Aug 17.

23.

Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant?

Swerdlow NR, Light GA.

Curr Top Behav Neurosci. 2016;28:305-25. doi: 10.1007/7854_2015_5012. Review.

PMID:
27311762
24.

Treat and Teach Our Students Well: College Mental Health and Collaborative Campus Communities.

Downs NS, Alderman T, Schneiber K, Swerdlow NR.

Psychiatr Serv. 2016 Sep 1;67(9):957-63. doi: 10.1176/appi.ps.201500465. Epub 2016 May 16. Review.

PMID:
27181737
25.

Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study.

Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW.

Schizophr Res. 2016 Jul;174(1-3):1-9. doi: 10.1016/j.schres.2016.04.011. Epub 2016 Apr 28.

26.

Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy.

Bhakta SG, Chou HH, Rana B, Talledo JA, Balvaneda B, Gaddis L, Light GA, Swerdlow NR.

Psychopharmacology (Berl). 2016 Jun;233(12):2399-410. doi: 10.1007/s00213-016-4291-0. Epub 2016 Apr 13.

27.

Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia.

Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff DL, Swerdlow NR, Light GA.

Schizophr Res. 2016 Apr;172(1-3):123-30. doi: 10.1016/j.schres.2016.01.019. Epub 2016 Feb 2.

28.

Reawakening research on reducing shock pain.

Swerdlow CD, Blumenthal T, Swerdlow NR.

Heart Rhythm. 2016 May;13(5):1149-1150. doi: 10.1016/j.hrthm.2016.01.017. Epub 2016 Jan 18. No abstract available.

PMID:
26795457
29.

Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study.

Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2016 Jan;170(1):30-40. doi: 10.1016/j.schres.2015.11.008. Epub 2015 Nov 18. Review.

30.

Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History.

Greenwood TA, Light GA, Swerdlow NR, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL.

Am J Psychiatry. 2016 Apr 1;173(4):385-91. doi: 10.1176/appi.ajp.2015.15050605. Epub 2015 Oct 6.

31.

Bending the curve on psychosis outcomes.

Light GA, Swerdlow NR.

Lancet Psychiatry. 2015 May;2(5):365-367. doi: 10.1016/S2215-0366(15)00172-8. Epub 2015 Apr 28. No abstract available.

32.

Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine.

Amitai N, Powell S, Weber M, Swerdlow NR, Young JW.

Cogn Affect Behav Neurosci. 2015 Dec;15(4):901-14. doi: 10.3758/s13415-015-0369-0.

33.

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.

Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA.

Neuropsychopharmacology. 2016 Jan;41(2):419-30. doi: 10.1038/npp.2015.162. Epub 2015 Jun 11.

34.

Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Light GA, Swerdlow NR.

Ann N Y Acad Sci. 2015 May;1344:105-19. doi: 10.1111/nyas.12730. Epub 2015 Mar 9. Review.

35.

Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2015 Apr;163(1-3):38-46. doi: 10.1016/j.schres.2015.01.017. Epub 2015 Mar 4.

36.

Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1).

Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF.

Schizophr Res. 2015 Apr;163(1-3):73-9. doi: 10.1016/j.schres.2015.01.027. Epub 2015 Feb 11.

37.

Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies.

Radant AD, Millard SP, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW.

Schizophr Res. 2015 Apr;163(1-3):47-52. doi: 10.1016/j.schres.2014.12.016. Epub 2014 Dec 29.

38.

California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS).

Stone WS, Mesholam-Gately RI, Braff DL, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ.

Schizophr Res. 2015 Apr;163(1-3):32-7. doi: 10.1016/j.schres.2014.10.029. Epub 2014 Dec 12.

39.

Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research.

Swerdlow NR, Gur RE, Braff DL.

Schizophr Res. 2015 Apr;163(1-3):9-16. doi: 10.1016/j.schres.2014.09.047. Epub 2014 Oct 24. Review.

40.

Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.

Light GA, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI.

Schizophr Res. 2015 Apr;163(1-3):63-72. doi: 10.1016/j.schres.2014.09.042. Epub 2014 Oct 23.

41.

Neurocognitive performance in family-based and case-control studies of schizophrenia.

Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE.

Schizophr Res. 2015 Apr;163(1-3):17-23.

42.

The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis.

Tarasenko MA, Swerdlow NR, Makeig S, Braff DL, Light GA.

Front Psychiatry. 2014 Oct 13;5:142. doi: 10.3389/fpsyt.2014.00142. eCollection 2014.

43.

The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2.

Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G.

Schizophr Res. 2015 Apr;163(1-3):53-62. doi: 10.1016/j.schres.2014.09.024. Epub 2014 Oct 11.

44.

Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications.

Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2015 Apr;163(1-3):24-31. doi: 10.1016/j.schres.2014.08.014. Epub 2014 Sep 22.

45.

Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings.

Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM.

Psychiatry Res. 2014 Sep 30;219(1):67-71. doi: 10.1016/j.psychres.2014.05.035. Epub 2014 May 28.

46.

Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study.

Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Bull. 2014 Nov;40(6):1404-11. doi: 10.1093/schbul/sbu064. Epub 2014 Jun 5.

47.
48.

Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS.

Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2014 Feb;152(2-3):503-12. doi: 10.1016/j.schres.2013.12.004. Epub 2014 Jan 7.

49.

Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Perez VB, Swerdlow NR, Braff DL, Näätänen R, Light GA.

Biomark Med. 2014;8(1):9-14. doi: 10.2217/bmm.13.133. No abstract available.

50.

Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats.

Swerdlow NR, Light GA, Trim RS, Breier MR, Hines SR, Powell SB.

Behav Brain Res. 2013 Nov 15;257:118-28. doi: 10.1016/j.bbr.2013.09.005. Epub 2013 Sep 25.

Supplemental Content

Loading ...
Support Center